BOSTON--(BUSINESS WIRE)--Several of the world’s top genetic testing laboratories are accelerating genetic disease diagnostics by integrating FDNA’s next-generation phenotyping (NGP) technologies into their workflow. Piloted earlier this year, FDNA’s Face2Gene LABS and Face2Gene CONNECT API are now available to all labs. Among those announcing partnership include GeneDx, Blueprint Genetics, Ambry Genetics, Variantyx and Fulgent Genetics, among others.
The integration will help clinicians quickly evaluate patients' clinical signs to highlight possible underlying disease-causing genetics through artificial intelligence and facial analysis. This new LABS capability allows clinicians using Face2Gene CLINIC to securely pass patient phenotypes and facial analysis insights to the lab to improve the speed and accuracy of a diagnosis.
Research shows that for rare diseases, genetic testing alone yields a diagnosis in only one of four cases. When coupled with facial analysis and phenotypic data, diagnoses can jump dramatically.
"With the world’s top labs adopting FDNA technology, the combination of next-generation sequencing with next-generation phenotyping is fast becoming the new standard in rare disease diagnosis,” Dekel Gelbman, CEO of FDNA, said in a statement. "We look forward to a new era of precision medicine where we can deliver faster, more precise answers for patients and their families.”
In the United States alone, one in 10 people suffer from a rare genetic disorder, yet surprisingly few have been given a precise diagnosis. Providing a diagnosis is for patients, families and care providers to better understand and prepare for what lies ahead.
Face2Gene is currently used by more than 70% of clinical geneticists worldwide as a means to evaluate syndromes, genes and phenotypes that correlate with patients’ facial and clinical analysis. With this integration, clinicians using Face2Gene can now send clinical genomic insights directly into the bioinformatics pipeline, speeding analysis while improving the diagnostic yield of molecular interpretation.
About FDNA and Face2Gene
FDNA is the developer of
Face2Gene, a clinical suite of phenotyping applications that facilitates
comprehensive and precise genetic evaluations. Face2Gene uses facial
analysis, deep learning and artificial intelligence to transform big
data into actionable genomic insights to improve and accelerate
diagnostics and therapeutics. With the world’s largest network of
clinicians, labs and researchers creating one of the fastest growing and
most comprehensive genomic databases, FDNA is changing the lives of rare
disease patients. For more information, visit www.FDNA.com.
Face2Gene is a registered trademark of FDNA INC.
